PATENT CLAIM ANALYSIS

Application Number: 16180612
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["549", "029000"]

Abstract:
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) and Formula (II) as follows: wherein Y, R 1 , G, and Q are defined herein;and  wherein R 11 , R 21 , R 41 , R B1  and G 1 , are defined herein.

Claim (Index 38):
A method of treating a condition selected from the group consisting of obesity, obesity related disorders, impaired oral glucose tolerance, insulin resistance, Type II diabetes mellitus, metabolic syndrome, metabolic syndrome X, dyslipidemia, elevated LDL, elevated triglycerides, obesity induced inflammation, osteoporosis and obesity related cardiovascular disorders comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of  claim 27 .

Metadata:
- Claim Count in Document: 68.0
- Percentile: 98.0
- Lexical Diversity: 1.7619
- Patent Class: 549.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14200108', '14200127', '14200097', '14200114', '15228042']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8121538551413778
- 35 USC 102 Novelty (BERT): 0.6519610451046444
- Combined Prediction Score: 0.7961345741377045
- Mean Citation Score: 547.1481980000002
- Max Citation Score: 687.37866
- Similarity Product: 596.1044957382525

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test